ABSTRACT

Despite their being uncommon, severe cutaneous adverse drug reactions (SCARs) result in a very great burden of disease. These reactions not only carry with them a high mortality (10%–50%) and high morbidity (60%) with severe ocular complications, alopecia, oral and dental complications and development of autoimmune diseases, but also create a substantial economic burden for patients’ families and society. SCARs are, therefore, an important medical problem needing a solution in many countries, especially in Asia.

The clinical spectrum of SCARs comprises Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS (drug rash with eosinophilia and systemic symptoms) (also known as drug hypersensitivity syndrome or drug-induced hypersensitivity syndrome) and acute generalised exanthematous pustulosis. Recent crucial advances in determining genetic susceptibility and understanding how T cells recognise certain medications or their metabolites via the major histocompatibility complex and the effects of cofactors, have led to the implementation of cost-effective screening programs enabling prevention in a number of countries, and to further understanding of the patho-mechanisms involved in SCARs and their significance.

In this review, we document comprehensively the journey of SCARs from bedside to bench and outline future perspectives in SCARs research.

Keywords: Severe cutaneous adverse drug reactions; Human leukocyte antigen; T-cell-mediated reactions

CLINICAL MANIFESTATIONS OF SEVERE CUTANEOUS ADVERSE DRUG REACTIONS

Adverse drug reactions (ADRs) are estimated to cause approximately 3%–6% of all hospital admissions, occur in 10%–15% of patients and have a fatality rate of 0.32% in hospitalized patients [1-3]. Rawlins and Thompson [4], classified ADRs into 2 types, A and B. Type A,
the predictable reactions, account for more than 80% of ADRs and relate to overdosage and the pharmacological activities of given drugs. The unpredictable reactions, type B, are responsible for fewer than 20% of ADRs and comprise both immune-mediated and non-immune-mediated reactions. Immune-mediated reactions have been classified by Gell and Coombs into 4 main subtypes of reactions (Fig. 1) [5]. Of these subtypes, IgE-mediated and delayed hypersensitivities are the most common.

Approximately one-fifth of all drug-induced ADRs are cutaneous adverse reactions and affect 2%–3% of hospitalized patients [6]. Severe cutaneous adverse reactions (SCARs), a form of T-cell-mediated hypersensitivity, account for approximately 2% of drug-induced cutaneous adverse reactions. The clinical spectrum of SCARs comprises Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug rash with eosinophilia and systemic symptoms (DRESS) (also known as drug hypersensitivity syndrome [HSS] or drug-induced hypersensitivity syndrome [DIHS]), and acute generalised exanthematous pustulosis (AGEP) [7]. Clinical and laboratory manifestations of severe cutaneous adverse drug reactions are summarised in Table 1 and the classification of adverse drug reactions is depicted in Fig. 1.

Despite their being uncommon, SCARs, especially SJS/TEN and HSS/DRESS, result in a very great burden of disease. These reactions not only carry with them a high mortality (10%–50%) and high morbidity (60%) with severe ocular complications, alopecia and oral and dental complications [8], but also create a substantial economic burden for patients’ families and society [9]. The fatalities typically occur in otherwise healthy individuals. Moreover,
a minority of these patients may develop autoimmune diseases and/or an increased risk of reactions to other medications [9].

Risk factors for drug-induced SCARs are manifold and related to both the drugs and the drug users [10] (Fig. 2). Genetic risk factors are, however, the most important, remarkably so in carbamazepine (CBZ), abacavir (ABC), and allopurinol-induced SCARs.

**Stevens-Johnson syndrome/toxic epidermal necrolysis**

The incidence of SJS and TEN is estimated to be approximately 1 to 6 cases and less than 2 cases in every 1 million people per year, respectively [11-13], depending upon the use of certain drugs and the presence of infectious conditions. Leading causative medications for SJS/TEN are antibiotics, anticonvulsants, allopurinol and nonsteroidal anti-inflammatory agents [14-16]. Interestingly, in Japan, Yamane et al. [17] reported that 69% of SJS and all TEN cases are associated with CBZ, whilst allopurinol has been found to be the most common cause of SJS in Europe and Israel [18]. In the human immunodeficiency virus (HIV) cohort the incidence of SJS is 10 times higher than in the general population [19]. In addition, infectious diseases caused by Mycoplasma pneumonia and Herpes simplex have been reported as causes of SJS/TEN without the involvement of medications [20, 21]. In Vietnamese patients with CBZ-induced SCARs, a history of Herpes virus infection has been reported to be more frequent than it is in tolerant controls (odds ratio, 9.78; 95% confidence interval [CI], 1.17–81.43; \( p = 0.02 \)) [22].
Clinical manifestations characteristic of SJS/TEN include skin detachment and mucosal erosions. The first symptoms and signs of these reactions typically occur after several days (within 4 weeks) of using the medication (index-day) [22]. The index-day occurs earlier if a patient with a history of SCAR is re-exposed to the culprit medication. The early symptoms of SJS/TEN are fever higher than 38°C, ocular discomfort and sore throat. Mucous membrane involvement then occurs and skin lesions appear and become more generalised over time [9]. The common lesions in the mucous membranes are erythema, blisters and erosions which can affect the eyes, nasopharynx, oropharynx, genitalia or anus (Fig. 3). The skin lesions in SJS/TEN manifest initially as erythema and atypical target lesions which are either macular or maculopapular. These lesions coalesce and may form very large blisters (greater than 5-cm diameter). In TEN, necrotic lesions can become generalised rapidly. The epidermal sheet detaches and sloughs under pressure (Nikolsky’s sign) (Fig. 3C). SJS is distinguished from TEN by the extent of the body surface area (BSA) involved in skin detachment. SJS is defined as skin detachment of less than 10% of BSA whereas TEN is more extensive with skin detachment in 30% of BSA or greater. Skin detachment of between 10%–20% of BSA is defined as an overlapping phenotype of SJS and TEN.

Internal organ involvement in SJS/TEN in the acute phase is manifest mainly as mild hepatic injury with transient elevated transaminases, kidney impairment and/or epithelial necrosis of the digestive tract and/or the respiratory tract [23-25]. The reported failure of internal organs which occurs in some patients is believed to be due to infection caused by leukopenia and loss of the skin barrier and electrolyte and fluid balance disturbances due to loss of fluids and electrolytes into the extensive blisters.

The severity of the disease is measured by SCORTEN (maximum 7) (severity-of-illness score for TEN) that has been defined as seven criteria consisting of age (over 40 years), heart rate (more than 120 bpm), presence of malignant disease, skin detachment (greater than 10% of BSA), serum urea level (>10 mmol/L), bicarbonate level in arterial blood (<20 mmol/L), and blood glucose (>14 mmol/L). The higher the SCORTEN, the higher the mortality rate [26].
Long-term complications after recovery from SJS/TEN are common. Most result from adhesions of the mucous membranes and strictures in the digestive or respiratory tracts [25, 27-30]. Some require surgical intervention [31]. Especially common are severe ocular complications such as symblepharon, severe dry eye, trichiasis, and conjunctival invasion into the cornea, which sometimes cause visual disturbance [32-34]. There is one case report of cirrhosis as a delayed complication of SJS [35].

The treatment of SJS/TEN, consists of withdrawing suspected medications and symptomatic and supportive treatment. Identification and discontinuation of the suspected medication is associated with better outcomes while delayed discontinuation or long half-lives of culprit medications increases morbidity and mortality [9]. Supportive and symptomatic care entails restoring fluid balance, providing nutrients, limiting pain, providing skin care and preventing fatal complications. In SJS/TEN, patients have an increased risk of fluid and protein leakage, leading to hypovolemia, functional renal insufficiency, and thermal dysregulation. Fluid replacement should be given as early as possible and adjusted daily [36]. High protein and high calorie nutritional therapy delivered by nasogastric tube is also recommended [9, 36]. Patients with SCARs are at high risk of infection due to leukopenia and open wounds; however, antibiotic therapy is only indicated when infection is present [9] and antibiotics are not recommended prophylactically. Wound care and minimising skin detachment, avoiding adhesions and functional complications of mucus membranes are the targets of skin care in SJS/TEN patients. Treatment in a burns unit, with the room temperature between 30°C–32°C is recommended [36].
In parallel with supportive and symptomatic care, targeted treatments may be given (Table 2). The use of all of these treatments; corticosteroids, intravenous immunoglobulin and cyclosporine, remains controversial. The tumor necrosis factor inhibitor, etanercept, has been reported to be of benefit in encouraging skin healing without complication, presumably by reducing epithelial cell apoptosis [9, 37].

**Hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms**

Unlike SJS/TEN, HSS/DRESS is characterised by nonbullous skin lesions and involvement of internal organs. The incidence of HSS/DRESS ranges from 1/1,000 to 1/10,000 drug users [38]. It has a mortality rate of up to 10% [39, 40]. A number of medications such as allopurinol, aromatic anticonvulsants, sulphonamides, dapsone, and minocycline have been described as causes of HSS/DRESS [38, 41, 42], however, allopurinol seems to be the most frequent culprit [41, 43].

Early symptoms of HSS/DRESS are flu-like symptoms, including fever higher than 38°C and skin rashes. Misdiagnosis is not uncommon because the index-day is frequently long, between 2–6 weeks [43]. A variety of skin lesions can be seen in HSS/DRESS such as maculopapular/morbilliform rashes, exfoliative dermatitis and desquamation [43]. Additional signs which have been reported in HSS/DRESS are facial or peripheral oedema, lymphadenopathy with palpable lymph nodes (>1 cm and >2 sites) and, rarely, mucosal involvement.

Internal organ involvement in HSS/DRESS is the result of an infiltration of eosinophils or lymphocytes in tissues [9]. The main organs affected are the liver (manifest as elevated transaminase levels) and the kidney (characteristically interstitial nephritis) [43]. Eosinophilic pneumonitis, meningitis, myocarditis, and pancreatitis have also been noted [41]. Haematological abnormalities in HSS/DRESS are eosinophilia (>1,500 cells/µL), atypical lymphocytes, leucocytosis and sometimes thrombocytopenia. In addition, the association of

| Clinical phenotypes | Targeted treatments | Outcomes |
|---------------------|---------------------|----------|
| **SJS/TEN**         | Corticosteroid [130-132] | -As empirical treatment, IV methylprednisolone 1–2 mg/kg/day, up to 600–1,000 mg/day (pulse therapy) |
|                     |                      | -Related to increasing hospitalisation period and infection. Not related to mortality rate in acute phase of SJS/TEN |
|                     | IVIg [36, 133, 134]  | -Consensus favours therapy for SJS/TEN |
|                     |                     | -No significant difference in mortality rate in comparison with corticosteroids and supportive and symptomatic care only |
|                     | Cyclosporine [135, 136] | -No significant difference in mortality rate between high dose and low dose IVIg |
|                     | Anti-TNF agents (etanercept and infliximab) [37, 137-139] | -Dose 3-10 mg/kg/day, short term |
|                     |                      | -Reduces mortality rate in comparison with IVIg |
| **HSS/DRESS**       | Corticosteroid [44, 140] | -Benefit in healing skin lesions |
|                     |                      | -Benefit in survival rate |
|                     | IVIg [9, 141, 142]   | -Systemic corticosteroids (IV or oral) for severe HSS/DRESS |
|                     |                      | -Topical corticosteroids for mild to moderate HSS/DRESS |
|                     |                      | -Related to complications, poorly efficacious even though IVIg has antiviral and immunomodulatory properties |
|                     |                      | -Benefit in DRESS resistant to systemic corticosteroid |
| **AGEP**            | Corticosteroid [143] | -No longer used because of poor efficacy and toxicity |

SJS/TEN, Stevens-Johnson syndrome/toxic epidermal necrolysis; IV, intravenous; IVIg, intravenous immunoglobulin; TNF, tumor necrosis factor; HSS/DRESS, hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms; AGEP, acute, generalised, exanthematous pustulosis.
virus infections (human herpes virus, Epstein-Barr virus, cytomegalovirus) with HSS/DRESS has been confirmed by polymerase chain reactions, with an IgM positive or an IgG rise [41].

In HSS/DRESS treatment, as in other forms of SCARs, suspected culprit medications must be discontinued as soon as possible. Suitable skin moisturisers reduce burning and pruritus, however, unlike in SJS/TEN, targeted treatment of HSS/DRESS is important [9]. Corticosteroids have frequently been shown to be efficacious; delivered systemically when severe with organ involvement and topically in mild to moderate HSS/DRESS [9], however, premature discontinuation or rapid dosage decreases are associated with relapses. In a retrospective study of 38 cases with DRESS, topical steroid was superior to a systemic regimen in preventing relapse; however, the authors acknowledged that selection bias may have influenced the results [44]. Intravenous immunoglobulin has also been used as a therapy for HSS/DRESS because of its antiviral and immunomodulatory effects, however, its use, in general, may be complicated by severe malaise and pulmonary embolism [45]. When there is evidence for viral infection or reactivation in HSS/DRESS [46], antiviral agents such as ganciclovir and valganciclovir hydrochloride have been given [47], however, poor efficacy and toxicity have been noted.

Long-term complications commonly associated with HSS/DRESS include autoimmune diseases such as Graves’ disease, Hashimoto’s disease, thyroiditis and type 1 diabetes [48].

Acute generalised exanthematous pustulosis
AGEP is characterised by the rapid development of a pustular eruption, a fever higher than 38˚C and an elevated white cell count, usually occurring within 48 hours of patients commencing the culprit drug. The index-day ranges from 48 hours to less than 2 weeks [9]. Although occasionally viral infections have been involved, drugs are the cause in more than 90% of AGEP [49]. In the EuroSCAR study, the most common causative medications were antibiotics such as pristinamycin, quinolones, ampicillin/amoxicillin, whilst anticonvulsants were rarely responsible. Pre-existing infection did not increase the risk of developing the complication of infection [50]. Most AGEP are benign and spontaneous recovery occurs after 2 weeks [51]. In severe AGEP, mucous membrane and internal organs can be involved. The mortality rate of AGEP is around 2%, 5 to 10 times less than in HSS/DRESS and SJS/TEN, respectively [15].

Overlapping clinical phenotypes of SCARs
Although very rare, overlap clinical phenotypes among SCARs have been reported [7, 52]. The clinical manifestations can overlap between SJS/TEN and AGEP, SJS/TEN and HSS/DRESS [53] and AGEP and HSS/DRESS [54]. The diagnosis of overlap is based on clinical morphology and skin biopsy findings [7, 55] (Fig. 3).

HLA AND SEVERE CUTANEOUS ADVERSE DRUG REACTIONS
Strong associations between human leukocyte antigen (HLA) and SCARs were first discovered in ABC-induced hypersensitivity where an association with HLA-B*57:01 [56, 57] was found in Caucasians and then CBZ and allopurinol-induced SCARs were found to be associated respectively with HLA-B*15:02 (2004) [58] and HLA-B*58:01 (2005) [59].
During the last decade, a number of HLA alleles have since been reported to confer susceptibility to drug-induced hypersensitivity, such as HLA-Cw8 in nevirapine hypersensitivity [60], HLA-B*73:01 in oxicam SCARs [61], HLA-B*59:01 with methazolamide-induced SJS [62], HLA-A*31:01 and CBZ-induced SCARs [63], and HLA-B*13:01 and dapsone hypersensitivity [64, 65]. Several populations in the Asia Pacific region have genetic susceptibilities for CBZ and allopurinol-induced SCARs.

**Genetic susceptibility to CBZ-induced SCARs**

CBZ, an aromatic amino anticonvulsant, employed since 1965 for multiple indications such as epilepsy, mental disorders and neurologically-based conditions, has been the most frequently prescribed anticonvulsant world-wide for both adults and children [66, 67]. The incidence of CBZ hypersensitivity is around 5%–10% with a wide clinical spectrum and it accounts for 4.1%–5.9% of SJS/TEN [68]. The incidence of CBZ-induced SCARs in Asians is approximately ten times higher than that in Caucasians [68, 69] and whilst non-genetic risk factors exist (age, sex, and comorbidities), a crucial role is played by pharmacogenetic risk factors.

**HLA-B*15:02**

Genetic susceptibility to CBZ-induced SCARs has been described in a number of populations (Table 3). The most striking genetic association was detected in a cohort of Han Chinese in Taiwan where HLA-B*1502 was found in 100% of 44 patients with CBZ-induced SJS/TEN (OR, 2504; 95% CI, 126–49,552) [58]. These findings were replicated in an extended cohort of subjects of Chinese descent originating from separate geographic areas of China [70-73], Taiwan [74], and Hong Kong [75]. In addition, HLA-B*15:02 has also been reported as a genetic susceptibility factor in CBZ-induced SJS/TEN in Thailand [76], Malaysia [77], Singapore [78], Vietnam [22, 79], and India [80]. Although the association between the HLA-B*15:02 allele and CBZ-induced SJS/TEN is very strong in almost all Asians, this was not found to be so in Europeans [63, 81], Japanese [82], and Koreans [83], which is likely due to the variable distribution of HLA-B*15:02 in different populations (prevalence very high in China, Southeast Asia, and India and very low in Europe, Japan, and Korea) [84].

**HLA-A*31:01**

The association between HLA-A*31:01 and all phenotypes of CBZ-induced SCARs has been confirmed in Caucasians [63] and Japanese [82] who have a high allele frequency (up to 0.084 in Japanese) [84]. In a Japanese study, Ozeki et al. [82] observed HLA-A*31:01 was present in 37 of 61 patients with SCARs, significantly higher than in the general population (OR, 10.8; 95% CI, 5.9–19.6). Similarly, McCormack et al. found in Europeans that HLA-A*31:01 was associated with all types of CBZ-induced SCARs in SJS (OR, 25.93; 95% CI, 4.93–116.18) and HSS (OR, 12.41; 95% CI, 1.27–121.03) [85]. In contrast, studies in Canada [86], Korea [83] and Taiwan [74], have confirmed HLA-A*31:01 is a genetic risk factor for only non-bullous skin reactions such as HSS and MPE, and not for SJS/TEN [69]. Genin’s meta-analysis in different ethnic groups concluded HLA-A*31:01 is a strong genetic susceptibility gene for DRESS (pooled OR, 13.2; 95% CI, 8.4–20.8) and only very weakly associated with CBZ-induced SJS/TEN (pooled OR, 3.94; 95% CI, 1.4–11.5) [69].

**HLA-B*15:11**

An association between HLA-B*15:11, a member of the HLA-B75 serotype with HLA-B*15:02, and CBZ-induced SCARs, albeit weak, has also been demonstrated in Asian populations. This risk allele can be responsible for bullous cutaneous adverse reactions [87].

[59] in Han Chinese. During the last decade, a number of HLA alleles have since been reported to confer susceptibility to drug-induced hypersensitivity, such as HLA-Cw8 in nevirapine hypersensitivity [60], HLA-B*73:01 in oxicam SCARs [61], HLA-B*59:01 with methazolamide-induced SJS [62], HLA-A*31:01 and CBZ-induced SCARs [63], and HLA-B*13:01 and dapsone hypersensitivity [64, 65]. Several populations in the Asia Pacific region have genetic susceptibilities for CBZ and allopurinol-induced SCARs.
Japanese (28.6%) with typical or atypical SJS/TEN, Kaniwa et al. [88] determined 4 with SJS/TEN (28.6%) were positive for HLA-B*15:11 compared with 1% of controls and none of the patients possessed HLA-B*15:02. They concluded HLA-B*15:11 is also a genetic risk factor for CBZ hypersensitivity. In Korea, HLA-B*15:11 was found to be present in 43% (3 of 7) SJS/TEN Korean patients in comparison with 4% of controls [88]. Due to their small sample size, no statistically significant difference was observed. In comparison with healthy Korean controls, the presence of this allele was significantly higher (OR, 18.4; 95% CI, 3.8–88.0; \( p < 0.05 \)) [83].

Sun et al. [73] found 1 of 11 Chinese CBZ-induced SJS/TEN patients negative for HLA-B*15:02, who possessed HLA-B15:11. In Vietnamese patients, HLA-B*15:11 was not observed to be associated with CBZ-induced SCARs [22]. Despite the controversial and weak nature of this possible association, Amstutz et al. [89] recommended this possible association be further tested in larger studies because this allele was absent in 8 European patients and only present in 1 of 42 Thai patients with CBZ-induced SJS/TEN [83]. In a systematic review, examining pooled results from 20 studies, Grover and Kukreti [87] compared the prevalence of HLA-B*15:11 in 720 CBZ-induced SJS/TEN with that in 1,113 CBZ-tolerant controls. This revealed that HLA-B*15:11 appears to be a genetic risk factor for CBZ-induced SCARs in Asians (OR, 17.43; 95% CI, 3.12–97.40; \( p = 1.1 \times 10^{-3} \)). In line with this finding, in 2017, Shi et
al. [90] reported HLA-B*15:11 is strongly associated with CBZ-induced SJS in Chinese (OR, 30.77; 95% CI, 1.63–580.87, \( p = 0.003 \)).

**Other genetic variants associated with CBZ-induced SCARs**

In 2001, Pirmohamed et al. [91] reported a polymorphism in the tumor necrosis factor (TNF)-\( \alpha \) gene promoter region related to CBZ-induced serious hypersensitivity in Caucasians (OR, 2.4; 95% CI, 1.2–4.8), which was not observed, however, in the Genome-Wide Association Study conducted by Hung et al. in Taiwanese [74].

**Variants protective against CBZ-induced SCARs**

HLA-B*40:01 reportedly protects Han Chinese from bullous CBZ-induced SCARs [87, 92] and Alfrevic et al. [93], in 2006, reported three "heat-shock protein cluster" (HSP 70) genes (Chromosome 6, MHC class III), as being protective against serious CBZ hypersensitivity reactions. Their findings did not allow them to conclude whether this gene group is responsible or whether it reflects linkage with other polymorphisms or genes. Recently, Nguyen et al. [22] found in Vietnamese patients that HLA-B*46:01 was present more frequently in CBZ tolerant individuals versus CBZ-induced SJS/TEN/DRESS patients (OR, 0.27; 95% CI, 0.08–0.94). They noted, however, that HLA-B*46:01 is the second most frequent allel in the Vietnamese population and postulated that this observation resulted from the prevalence of HLA-B*15:02 in the patient group engendering an unequal presence of HLA-B*46:01 allele in the 2 groups.

HLA-A*24:02 appears to be a controversial genetic factor. In 2014, in their review, of patients classified by clinical phenotype, Grover and Kukreti [87] found that the allele HLA-A*24:02 is a protective variant for SJS/TEN in Asians (OR, 0.27; 95% CI, 0.11–0.64; \( p = 2.7 \times 10^{-3} \)). In 2017, HLA-A*24:02, however, was reported to be a risk factor for CBZ-induced SJS in Chinese albeit with a weak association (OR, 2.33; 95% CI, 1.16–4.69; \( p = 0.015 \)) [90].

**Genetic susceptibility to allopurinol-induced SCARs**

Since the 1960s, allopurinol, a xanthine oxidase inhibitor, has been used as first-line therapy for gout, hyperuricaemia related to cell-lysing therapy in malignant diseases and kidney stones associated with hyperuricosuria.

**HLA-B*58:01**

Allopurinol-induced SCARs, have also been found to result from a major genetic susceptibility factor-HLA-B*58:01 (Table 4). In 2005, Hung et al. [59] demonstrated a strong association between HLA-B*58:01 and allopurinol-induced SCARs in Han Chinese in Taiwan, with HLA-B*58:01 present in all 51 patients with SCARs (21 TEN, 30 DIHS patients) while it was identified in only 21 of 135 allopurinol tolerant controls (OR, 580.3; 95% CI, 34.4–9780.9). Their findings have been reproduced in other Asian populations; Thai [94], Korean [95] and Japanese [96], and a meta-analysis of 6 Asian studies, by Somkrua et al. [97] reported a high pooled odds ratio of 96.60 (95% CI: 24.49–381.00). This strong association has also been reported across European populations [61, 98, 99].

Unlike with HLA-B*15:02, where the allele is only associated with CBZ-induced SJS/TEN in Asians and not HSS/DRESS, HLA-B*58:01 appears to be the common genetic risk factor for allopurinol-induced SCARs worldwide, probably due to the distribution of HLA-B*58:01 being comparable in Asians and Europeans. However, why this risk allele is not phenotype specific remains unknown.
HLA-A*33:03 and HLA-Cw*03:02

HLA class I alleles, other than HLA-B*58:01, have been reported as being associated with allopurinol-induced SCARs; HLA-A*33:03 in the Korean, Japanese [96] and Italian populations [99] (Table 4). HLA-B*58:01, however, appears to be the most important genetic risk factor because it best predicts allopurinol-induced SCARs [95].

**CURRENT UNDERSTANDING OF PATHO-MECHANISMS IN HLA-ASSOCIATED CBZ AND ALLOPURINOL-INDUCED SCARS**

HLAs and TCRs

Principally, HLA molecules contribute to drug hypersensitivity reactions in the antigen presenting phase of T-cell-mediated immune responses. The susceptibility HLA proteins can present specific medication or a metabolic product of that medication to naïve CD8 T cells by Hapten/Pro-hapten, pharmacological interaction (P-I) or Altered peptide repertoire models (Fig. 4). Once these antigens are recognized by specific T-cell receptors (TCR), the effector phase of the immune response will occur, resulting in the proliferation of CD8 T cells and the release of cytokines [9, 100, 101]. Both CBZ and allopurinol and their metabolites are presented to T cells by antigen presenting cells (APC) without a requirement for intracellular antigen processing [102], consistent with the P-I model [103].

**CBZ-induced SCARs**

In CBZ-induced SJS/TEN, Wei et al. [104] proved in vitro that CBZ or its active metabolites can interact directly with HLA-B*15:02 peptide to form the complex of HLA-B*15:02 peptide/beta-2 microglobulin/CBZ and TCR that can activate CD8 T cells. The activation of CD8 T cells leads to the apoptosis of keratinocytes resulting from the degranulation of perforin and granzyme B and Fas/FasL interaction [105]. Furthermore, Chung et al. [106] compared global gene expression between cells obtained from active lesions and peripheral blood mononuclear cells (PBMCs) and found granulysin, a biomarker for cell-mediated immune responses, increased when natural killer (NK) cells and cytotoxic T cells were activated. The
The authors concluded that this biomarker plays a central role in the apoptosis of keratinocytes in SJS/TEN phenotypes. In summary, there are important contributions from cytokines such as granulysin, perforin, granzyme B and TNF-α in SJS/TEN through the activation of CD8 T cells, following the recognition of HLA-specific drug complexes.

However, HLA does not play a role itself. In 2011, Ko et al. [107] compared the TCR profile on CBZ-specific T cells in SJS/TEN patients carrying HLA-B*15:02 with that of CBZ tolerant patients and healthy individuals who have never been exposed to CBZ. The results showed that the TCR Vβ11-1-1SGSY clonotype was present mainly in SJS/TEN patients (16/19), absent in all CBZ tolerant patients (17) and present in only 4 of 29 healthy individuals without CBZ exposure. In addition, their functional study showed that in the PBMCs of healthy individuals who possess both HLA-B*15:02 and the TCR Vβ-11-ISGSY clonotype, CBZ-specific cytotoxicity could be primed in vitro. These results, therefore, indicate that T-cell stimulation occurs in CBZ-induced SJS/TEN only when both a specific HLA allele and a specific TCR clonotype are present. This finding is able to partly explain why the majority of HLA-B*15:02...
carriers can tolerate CBZ (97%) and why HLA-B*15:02 is specific for both the clinical phenotype and the patient’s ethnicity.

As previously described, unlike HLA-B*15:02, HLA-A*31:01 confers genetic susceptibility for all clinical phenotypes in CBZ-induced SCARs, mainly in Japanese [82] and Caucasians [63]. A functional study conducted by Lichtenfels et al. [108] revealed that HLA-A*31:01 is able to activate restrictedly CD8 T cells obtained from patients with CBZ-induced SCARs [108]. The authors also found involvement of HLA class II (HLA-DRB1*04:04) in the activation of CBZ-specific CD4 T cells that had been observed in Caucasian patients with CBZ-induced SCARs [109]. In addition, HLA-A*31:01 and HLA-DRB1*04:04 are in linkage disequilibrium, forming a common haplotype in Caucasians [108]. Therefore, Lichtenfels et al. proposed that this common haplotype can contribute to the response of multiclonal T cells seen in Caucasian patients with CBZ-induced SCARs, differing from Asian patients in whom little expansion of the CBZ-specific CD4 T cell population was observed [107, 108]. In view of these findings, it appears that the presence of HLA-A*31:01 is not involved in determining the specific clinical phenotype in CBZ-induced SCARs.

Allopurinol-induced SCARs

In allopurinol-induced SCARs, Yun et al. [110] carried out an experiment using PBMCs obtained from patients and it revealed that allopurinol and its early metabolite in plasma, oxypurinol, are able to bind the HLA-B*58:01 molecule in the F pocket of the peptide binding groove, resulting in activation of specific T cells. Moreover, the authors also found that the specific T cells do not use particular TCR repertoires to recognize the complex of allopurinol/oxypurinol and HLA-B*58:01 in allopurinol-induced SCARs.

Costimulation from innate immune responses

Innate immunity has been reported as an emerging cofactor in the context of the adaptive immune response in general and T-cell-mediated drug reactions in particular [111]. It has been implicated in reducing the threshold of T-cell activation [112]. In addition, gene expression profiling demonstrated a temporarily high level of gene transcriptions encoding for alarmin proteins in the acute phase of delayed drug hypersensitivity, especially in SJS/TEN [113]. Alarmins are able to recruit, activate APC and augment the adaptive immune response [114]. The involvement of the innate immune response, however, has been reported to be mainly related to dendritic cells (DCs).

In T-cell-mediated reactions, especially in the hapten or pro-hapten models, the drug or its metabolites have to be presented by mature DCs after intracellular antigen processing to be able to elicit T cell activation (Fig. 4). Therefore, it is likely that DCs play a role in the initial stages of drug sensitization. In the P-I models that do not require intracellular antigen processing, DCs have been shown to mature and be activated directly by drug or its metabolites as danger signals [103, 111]. For instance, in the case of allopurinol hypersensitivity, specific T cells have been reported to be directly and immediately activated by oxypurinol, an early metabolite of allopurinol in plasma, and bound to HLA-B*58:01 without intracellular antigen processing in DCs [110]. In line with these findings, allopurinol has also been reported to be able to induce an innate immune response in a human DC cell line [115]. Therefore, it is very likely that DCs in allopurinol-induced SCARs may be activated directly by allopurinol/oxypurinol acting as danger signals. Certain drugs can change the maturational status of DCs, increasing T-cell proliferation in allergic patients in comparison with tolerant controls [111]. In addition, there is evidence emerging which
demonstrates the involvement of innate immune responses in T-cell-mediated reactions in virally infected patients [10], in keeping with the hypothesis that viral infection might be able to alter the phenotype of DCs via Toll-like receptors that have the ability to present antigen to naïve T cells in draining lymph nodes after migrating to the nodes [111]. In addition, current evidence has revealed that T-cell-mediated drug reactions share characteristics with autoimmune diseases [116, 117], and it is proposed there may be a common pathway for both T-cell-mediated drug reactions and autoimmune diseases. Finally, in the context of interaction with other innate immune cells such as NK cells, the cross-talk may be crucial in determining whether T-cell activation occurs at the early stage of antigen recognition when the close interaction between adaptive immunity and innate immunity is formed [111]. Taken together, the evidence supports a role for innate immunity in T-cell-mediated reactions, mainly via the DCs.

FUTURE DIRECTIONS FOR RESEARCH IN HLA-ASSOCIATED SCARS

In the last decade, our knowledge of the patho-mechanisms in HLA-associated SCARs has grown considerably, particularly our understanding of the way in which T cells recognise their corresponding HLA molecules and of the role of cofactors, such as drug concentration and viral infection. Laboratory bench findings have been translated to the implementation and dissemination of HLA screening programs to prevent SCARs. Screening has not only prevented SCARs, it has freed up individuals without the risk alleles for treatment with the drugs which are the leading causes of SCARs. However, although the pharmacogenetic research has allowed us to prevent SCARs, as the majority of individuals (53% in ABC and 97% in CBZ and allopurinol), who possess these genetic risk alleles tolerate ABC, CBZ or allopurinol [10, 112], respectively, it has also become clear that DNA sequencing has been only the starting point of the story. A number of studies now have investigated the possible role of epigenetics (DNA methylation and posttranscription regulation by microRNAs) in the development of HLA-associated SCARs. As emerging evidence shows epigenetic factors play an important role in regulation of the immune system overall [118-122], further research into epigenetic influences in SCARs are drawing parallels with other immune conditions, such as systemic lupus erythematosus.

Apropos of epigenetic research, in 2017, Sun et al. [123] first studied a genome-scale DNA methylation profiling of 15 patients and 20 matched controls to determine there is an association between DNA methylation and allopurinol-induced SCARs, and validated their results by using pyro sequencing in 40 patients and 48 controls. The authors found 26 genes modified at 41 CpG islands. Of these, hypomethylation of PSORS1C1 (cg24926791) was significant in DRESS ($p = 0.00127$) and in SJS/TEN ($p = 3.75 \times 10^{-13}$) in comparison with the controls, respectively. This result suggested that the level of DNA methylation may be important in the development of allopurinol-induced SCARs. Further studies will be required to elucidate the exact role of this CpG island.

MicroRNAs (miRNAs) are short noncoding RNAs, 19–23 nucleotides long, which play various key roles in biological processes and regulation of immune responses have been estimated to regulate approximately 30% of human genes [124]. In regulating the immune response, miRNAs have been reported to be expressed specifically on different immune cells and are involved in differentiation, maturation and activation of cell effectors [125].
A number of miRNAs involved in T-cell-mediated ADRs have been identified. Overexpression of miR18a-5p in skin and serum has been demonstrated in patients with TEN, implying a link with epidermal necrolysis [126], whilst serum miR124 was proposed as a biomarker for TEN [127]. Moreover, a cellular study found that miR18a and miR155 in CBZ-specific CD4+T cells were up-regulated during their activation in a drug and time dependent manner, supporting the observations of their expression levels in serum or skin in patients [128]. More importantly, miR148a is able to regulate the expression level of HLA-C in HIV-infected patients in relation to the 3’ untranslated region of HLA-C, associated with control of HIV [129]. This finding represents an example of regulation of HLA class I expression through an interaction between a miRNA and a genetic polymorphism. Taken together, studying the role of epigenetics should lead to a better understanding of T-cell-mediated ADRs in general and HLA-associated SCARs in particular.

HLA-associated SCARs then, have journeyed from the bedside to the bench and have thus enabled their prevention by pharmacogenetic screening. Researchers are now poised to discover more of the basic molecular mechanisms in immunity in general as they investigate the patho-mechanisms in SCARs.

**ACKNOWLEDGEMENTS**

We are grateful to the Australian Government for funding Dr Dinh Van Nguyen’s Australia Awards Scholarship for his PhD (Medicine) studies at The University of Sydney. We also thank Quan Van Hong Nguyen, our resident for redrawing the figures (1 and 2) from Drs Baldo and Pham, who are pleased to have helped.

**REFERENCES**

1. Demoly P, Bousquet J. Epidemiology of drug allergy. Curr Opin Allergy Clin Immunol 2001;1:305-10. [PUBMED] [CROSSREF]
2. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279:1200-5. [PUBMED] [CROSSREF]
3. Thong BY, Tan TC. Epidemiology and risk factors for drug allergy. Br J Clin Pharmacol 2011;71:684-700. [PUBMED] [CROSSREF]
4. Rawlins MD, Thompson JW. Pathogenesis of adverse drug reactions. In: Davis DM, editor. Textbook of adverse drug reactions. Oxford: Oxford University Press; 1977. p. 10-31.
5. Gell PG, Coombs RR, editors. Clinical aspects of immunology. 1963, Oxford: Blackwell Scientific Publications; 1963.
6. Scherer K, Bircher AJ. Danger signs in drug hypersensitivity. Med Clin North Am 2010;94:681-9, xv-x. [PUBMED] [CROSSREF]
7. Bouvresse S, Valeyrie-Allanore L, Ortonne N, Konstantinou MP, Kardaun SH, Bagot M, Wolkenstein P, Roujeau JC. Toxic epidermal necrolysis, DRESS, AGEP: do overlap cases exist? Orphanet J Rare Dis 2012;7:72. [PUBMED] [CROSSREF]
8. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994;331:1272-85. [PUBMED] [CROSSREF]
9. Duong TA, Valeyrie-Allanore L, Wolkenstein P, Chosidow O. Severe cutaneous adverse reactions to drugs. Lancet 2017;390:1996-2011. [PUBMED] [CROSSREF]
10. White KD, Chung WH, Hung SI, Mallal S, Phillips EJ. Evolving models of the immunopathogenesis of T cell-mediated drug allergy: The role of host, pathogens, and drug response. J Allergy Clin Immunol 2015;136:219-34; quiz 35.

11. Rzany B, Mockenhaupt M, Stocker U, Hamouda O, Schöpf E. Incidence of Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with the acquired immunodeficiency syndrome in Germany. Arch Dermatol 1993;129:1059.

12. Yang MS, Lee JY, Kim J, Kim GW, Kim BK, Kim JY, Park HW, Cho SH, Min KU, Kang HR. Incidence of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Nationwide Population-Based Study Using National Health Insurance Database in Korea. PLoS One 2016;11:e0165933.

13. Diphoom J, Cazzaniga S, Gamba C, Schroeder J, Rivolta A, Vighi GD, Naldi L; REACT-Lombardia study group. Incidence, causative factors and mortality rates of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in northern Italy: data from the REACT registry. Pharmacoeconomics Drug Saf 2016;25:196-203.

14. Blumenthal KG, Wickner PG, Lau JJ, Zhou L. Stevens-Johnson syndrome and toxic epidermal necrolysis: a cross-sectional analysis of patients in an integrated allergy repository of a large health care system. J Allergy Clin Immunol Pract 2015;3:277-80.e1.

15. Mockenhaupt M, Viboud C, Dunant A, Naldi L, Haley S, Bouwes Bavinck JN, Sidoroff A, Schneck J, Roujeau JC, Flahault A. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 2008;128:35-44.

16. Ding WY, Lee CK, Choon SE. Cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia. Int J Dermatol 2010;49:634-41.

17. Yamane Y, Aihara M, Ikezawa Z. Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in Japan from 2000 to 2006. Allergol Int 2007;56:419-25.

18. Halevy S, Ghislain PD, Mockenhaupt M, Fagot JP, Bouwes Bavinck JN, Sidoroff A, Naldi L, Dunant A, Viboud C, Roujeau JC, Euro SS; EuroSCAR Study Group. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 2008;58:25-32.

19. Mittmann N, Knowles SR, Koo M, Shear NH, Rachlis A, Rourke SB. Incidence of toxic epidermal necrolysis and Stevens-Johnson Syndrome in an HIV cohort: an observational, retrospective case series study. Am J Clin Dermatol 2012;13:49-54.

20. Tomaino J, Keegan T, Miloh T, Kerkar N, Mercer S, Birge M, Rocca J, Suchy F, Arnon R. Stevens-Johnson syndrome after Mycoplasma pneumoniae infection in pediatric post-liver transplant recipient: case report and review of the literature. Pediatr Transplant 2012;16:E74-7.

21. Golden HE. Stevens-Johnson syndrome associated with herpes simplex virus. Arch Intern Med 1993;153:1396.

22. Nguyen DV, Chu HC, Nguyen DV, Phan MH, Craig T, Baumgart K, van Nuen S. HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in Vietnamese. Asia Pac Allergy 2015;5:68-77.

23. Kamada N, Kinoshita K, Togawa Y, Kobayashi T, Matsubara H, Kohno M, Igaru H, Kuriyama T, Nakamura M, Hirasa H, Shinkai H. Chronic pulmonary complications associated with toxic epidermal necrolysis: report of a severe case with anti-Ro/SS-A and a review of the published work. J Dermatol 2006;33:616-22.

24. Lehargy F, Wolkenstein P, Gisselbrecht M, Lange F, Fleury-Feith J, Delclaux C, Roupie E, Revuz J, Roujeau JC. Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study. Intensive Care Med 1997;23:1237-44.
25. Kamata T, Sakamaki F, Fujita H, Urano T, Mori M, Yamaguchi K, Kanazawa M, Kai M, Izumi T, Naka W, Nishikawa T, Kawashiro T. Toxic epidermal necrolysis with tracheobronchial and pulmonary complications. Intern Med 1994;33:252-5.

26. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000;115:149-53.

27. Tan YM, Goh KL. Esophageal stricture as a late complication of Stevens-Johnson syndrome. Gastrointest Endosc 1999;50:566-8.

28. Gotz-Wieckowska A, Bernardczyk-Meller J, Rakowicz P. Ocular complication in children with Stevens-Johnson syndrome. Klin Oczna 2003;105:414-6.

29. Wu MK, Chung W, Wu CK, Tseng PT. The severe complication of Stevens-Johnson syndrome induced by long-term clozapine treatment in a male schizophrenia patient: a case report. Neuropsychiatr Dis Treat 2015;11:1039-41.

30. Sangwan A, Saini HR, Sangwan P, Dahiya P. Stunted root development: a rare dental complication of Stevens-Johnson syndrome. J Clin Exp Dent 2016;8:e462-4.

31. Sedghizadeh PP, Kumar SK, Gorur A, Mastin C, Boros AL. Toxic epidermal necrolysis with a rare long-term oral complication requiring surgical intervention. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008;105:e29-33.

32. Ueta M. Genetic predisposition to stevens-johnson syndrome with severe ocular surface complications. Cornea 2015;34 Suppl 11:S158-65.

33. Ukponmwun CU, Njinaka I, Ehimiyan ET. Ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis. Trop Doct 2010;40:167-8.

34. Chhipa SA, Masood S, Salarzai Y, Khan QA, Ahmad K, Sajid S. Ocular manifestation, complications and aetiological factors in Stevens-Johnson syndrome/toxic epidermal necrolysis. J Pak Med Assoc 2015;65:62-4.

35. Nam YH, Lee SW, Lee SK, Roh MS, Jeong IH, Park SM, Yoon NB, Kim KH, Um SJ, Son CH. Liver cirrhosis as a delayed complication of Stevens-Johnson syndrome. Intern Med 2011;50:1761-3.

36. Schneider JA, Cohen PR. Stevens-Johnson syndrome and toxic epidermal necrolysis: a concise review with a comprehensive summary of therapeutic interventions emphasizing supportive measures. Adv Ther 2017;34:1235-44.

37. Paradisi A, Abeni D, Bergamo F, Ricci F, Didona D, Didona B. Etanercept therapy for toxic epidermal necrolysis. J Am Acad Dermatol 2014;71:278-83.

38. Hiranuntikhul A, Rattanaruangpong T, Klaewsongkram J, Rerknimitr P, Pongprutthipan M, Ruxuntham K. Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms (DIFHS/ DRESS): 11 years retrospective study in Thailand. Allergol Int 2016;65:432-8.

39. Descamps V. Drug reaction with eosinophilia and systemic symptoms (DRESS). Rev Prat 2012;62:1347-52.

40. Kardaun SH, Sekula P, Valevrie-Allanore L, Liss Y, Chu CY, Creamer D, Sidoroff A, Naldi L, Mockenhaupt M, Roujeau JC; RegiSCAR study group. Drug reaction with eosinophilia and systemic symptoms (DRESS); an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol 2013;169:1071-80.
43. Cacoub P, Musette P, Descamps V, Meyer O, Speirs C, Finzi L, Roujeau JC. The DRESS syndrome: a literature review. Am J Med 2011;124:588-97.
PUBMED | CROSSREF

44. Funck-Brentano E, Duong TA, Bouvresse S, Bagot M, Wolkenstein P, Roujeau JC, Chosidow O, Valerye-Allanore L. Therapeutic management of DRESS: a retrospective study of 38 cases. J Am Acad Dermatol 2015;72:246-52.
PUBMED | CROSSREF

45. Joly P, Janela B, Tetart F, Rogez S, Picard D, D’Incan M, Descamps V, Collet E, Roujeau JC, Musette P. Poor benefit/risk balance of intravenous immunoglobulins in DRESS. Arch Dermatol 2012;148:543-4.
PUBMED | CROSSREF

46. Kano Y, Hiraharas K, Sakuma K, Shiohara T. Several herpesviruses can reactivate in a severe drug-induced multiorgan reaction in the same sequential order as in graft-versus-host disease. Br J Dermatol 2006;155:301-6.
PUBMED | CROSSREF

47. Eshki M, Allanore L, Musette P, Milpied B, Grange A, Guillaume JC, Chosidow O, Guillot I, Paradis V, Joly P, Crickx B, Ranger-Rogeze S, Descamps V. Twelve-year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms: a cause of unpredictable multiorgan failure. Arch Dermatol 2009;145:67-72.
PUBMED | CROSSREF

48. Kano Y, Tohyama M, Aihara M, Matsukura S, Watanabe H, Sueki H, Iijima M, Morita E, Nihiha H, Asada H, Kabashima K, Azukizawa H, Hashizume H, Nagao K, Takahashi H, Abe R, Sotozono C, Kurosawa M, Aoyama Y, Chu CY, Chung WH, Shiohara T. Sequelae in 145 patients with drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms: survey conducted by the Asian Research Committee on Severe Cutaneous Adverse Reactions (ASCAR). J Dermatol 2015;42:276-82.
PUBMED | CROSSREF

49. De A, Das S, Sarda A, Pal D, Biswas P. Acute generalised exanthematous pustulosis: an update. Indian J Dermatol 2018;63:22-9.
PUBMED | CROSSREF

50. Sidoroff A, Dunant A, Viboud C, Halevy S, Bavinck JN, Naldi L, Mockenhaupt M, Fagot JP, Roujeau JC. Risk factors for acute generalized exanthematous pustulosis (AGEP) - results of a multinational case-control study (EuroSCAR). Br J Dermatol 2007;157:989-96.
PUBMED | CROSSREF

51. Sidoroff A, Halevy S, Bavinck JN, Vaillant L, Roujeau JC. Acute generalized exanthematous pustulosis (AGEP)--a clinical reaction pattern. J Cutan Pathol 2001;28:113-9.
PUBMED | CROSSREF

52. Casagranda A, Suppa M, Dehavay F, Del Marmol V. Overlapping DRESS and Stevens-Johnson syndrome: case report and review of the literature. Case Rep Dermatol 2017;9:1-7.
PUBMED | CROSSREF

53. Wolf R, Davidovici B, Matz H, Mahlab K, Orion E, Shoenegger ZM. Drug Rash with eosinophilia and systemic symptoms versus Stevens-Johnson Syndrome--a case that indicates a stumbling block in the current classification. Int Arch Allergy Immunol 2006;141:308-10.
PUBMED | CROSSREF

54. Roujeau JC, Bioulac-Sage P, Bourseau C, Guillaume JC, Bernard P, Lok C, Plantin P, Clady A, Delavriere C, Vaillant L, Wechsler J, Danan G, Benichou C, Beylot C. Acute generalized exanthematous pustulosis. Analysis of 63 cases. Arch Dermatol 1991;127:1333-8.
PUBMED | CROSSREF

55. Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, Sayer D, Casy A, Mamotte C, Maxwell D, James J, Christiansen FT. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002;359:727-32.
PUBMED | CROSSREF

56. Chung WH, Hung SI, Hsih MS, Yang LC, Ho HC, Wu YJ, Chen YT. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004;428:486.
59. Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, Lin YL, Lan JY, Yang LC, Hong HS, Chen MJ, Lai PC, Wu MS, Chu CY, Wang KH, Chen CH, Fann CS, Wu JY, Chen YT. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A 2005;102:4134-9.

60. Gatanaga H, Yazaki H, Tanuma J, Honda M, Genka I, Teruya K, Tachikawa N, Kikuchi Y, Oka S. HLA-Cw8 primarily associated with hypersensitivity to nevirapine. AIDS 2007;21:264-5.

61. Lonjou C, Borot N, Sekula P, Ledger N, Thomas I, Haley S, Naldi L, Bouwes-Bavinck JN, Sidoroff A, de Toma C, Schumacher M, Roujeau JC, Hovnanian A, Mockenhaupt M; RegiSCAR study group. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 2008;18:99-107.

62. Kim SH, Kim M, Lee KW, Kim SH, Kang HR, Park HW, Jee YK. HLA-B*5901 is strongly associated with methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. Pharmacogenomics 2010;11:879-84.

63. McCormack M, Alfirievic A, Bourgeois S, Farrell JJ, Kasperavičiūtė D, Carrington M, Sills GJ, Marson T, Jia X, de Bakker PJL, Chinthapalli K, Molokhia M, Johnson MR, O'Connor GD, Chaila E, Alshussaini S, Shinnan KV, Radtke RA, Heinzeman EL, Walley N, Pandolfo M, Pichler W, Park BK, Depondt C, Sisodiya SM, Goldstein DB, Deloukas P, Delanty N, Cavalleri GL, Pirmohamed M. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 2011;364:1134-43.

64. Tempark T, Satapornpong P, Rerknimitr P, Nakkam N, Saksit N, Wattanakrai P, Jantararoungtong T, Koomee N, Mahakanukrauh A, Tassaneeyakul W, Pratoomwun J, Klaewsongkram I, Rerkpattanapipat T, Sukasem C. Dapsone-induced severe cutaneous adverse drug reactions are strongly linked with HLA-B*13:01 allele in the Thai population. Pharmacogenet Genomics 2017;27:429-37.

65. Zhang FR, Liu H, Irwanto A, Fu XA, Li Y, Yu GQ, Yu YX, Chen MF, Low HQ, Li JH, Bao FF, Foo JN, Bei JX, Jia XM, Liu J, Liany H, Wang N, Niu GY, Wang ZZ, Shi BQ, Tian HQ, Liu LX, Ma SS, Zhou Y, You JB, Yang Q, Wang C, Chu TS, Liu DC, Yu XL, Sun YH, Ning Y, Wei ZH, Chen SL, Chen XC, Zhang ZX, Liu YX, Pulit SL, Wu WB, Zheng ZY, Yang RD, Long H, Liu ZS, Wang JQ, Li M, Zhang LH, Wang H, Wang LM, Xiao P, Li JH, Huang ZM, Huang JX, Li Z, Liu J, Xiong L, Yang J, Wang XD, Yu DB, Lu XM, Zhou GZ, Yan LB, Shen JP, Zhang GC, Zeng YX, de Bakker PJL, Chen SM, Liu JJ. HLA-B*13:01 and the dapsone hypersensitivity syndrome. N Engl J Med 2013;369:1620-8.
73. Sun D, Yu CH, Liu ZS, He XL, Hu JS, Wu GF, Mao B, Wu SH, Xiang HH. Association of HLA-B*1502 and *1511 allele with antiepileptic drug-induced Stevens-Johnson syndrome in central China. J Huazhong Univ Sci Technolog Med Sci 2014;34:146-50.

74. Hung SI, Chung WH, Jee SH, Chen WC, Chang YT, Lee WR, Hu SL, Wu MT, Chen GS, Wong TW, Hsiao PF, Chen WH, Shih HY, Fang WH, Wei CY, Lou YH, Huang YL, Lin Jj, Chen YT. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 2006;16:297-306.

75. Locharezkul C, Loplumlert J, Limotai C, Korkij W, Desudchit T, Kangwanshiratada O, Hirankarn N, Suphapeetiporn K, Shotelersuk V. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia 2008;49:2087-91.

76. Tassaneeyakul W, Tiamkao S, Jantaraaroungtong T, Chen P, Lin SY, Chen WH, Konyoung P, Khunarkornsi U, Auwichayapat N, Pavakul K, Kulpantrakorn K, Choonhkarn C, Phonhiamhan S, Piyaatrakul N, Aungaree T, Pongpakdee S, Yodnopaglaw P. Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population. Epilepsia 2010;51:926-30.

77. Chang CC, Too CL, Murad S, Hussein SH. Association of HLA-B*1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian population. Int J Dermatol 2011;50:221-4.

78. Chong KW, Chan DW, Cheung YB, Ching LK, Hie SL, Thomas T, Ling S, Tan EC. Association of carbamazepine-induced severe cutaneous drug reactions and HLA-B*1502 allele status, and dose and treatment duration in paediatric neurology patients in Singapore. Arch Dis Child 2014;99:581-4.

79. Lonjou C, Thomas L, Borot N, Ledger N, de Toma C, LeLouet H, Graf E, Schumacher M, Hovnanian A, Mockenhaupt M, Roujeau JC, Regli SG. A marker for Stevens-Johnson syndrome: ethnicity matters. Pharmacogenomics J 2006;6:265-8.

80. Mehta TY, Prajapati LM, Mittal B, Joshi CG, Sheth JL, Patel DB, Dave DM, Goyal RK. Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians. Indian J Dermatol Venereol Leprol 2009;75:579-82.

81. Alfirevic A, Jorgensen AL, Williamson PR, Chadwick DW, Park BK, Firimohamed M. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics 2006;7:813-8.

82. Ozeki T, Shindo T, Yoshinari T, Takahashi T, Kubo M, Shirakata Y, Ikekawa Z, Iijima M, Shiohara T, Hashimoto K, Kamatani N, Nakamura Y. Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet 2011;20:1034-41.

83. Kim SH, Lee KW, Song WJ, Kim SH, Jee YK, Lee SM, Kang HR, Park HW, Cho SH, Park SH, Min KU, Chang YS. Adverse Drug Reaction Research Group in Korea. Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans. Epilepsy Res 2011;97:190-7.

84. González-Galarza FF, Takeshita LY, Santos EJ, Kempson F, Maia MH, da Silva AL, Teles e Silva AL, Ghattaoraya GS, Alfirevic A, Jones AR, Middleton D. Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations. Nucleic Acids Res 2015;43:D784-8.

85. Abrams D, Nguyen LT, Murphy J, Lee YA, Tran NK, Wiljer D. Perceptions and experiences of perinatal mental disorders in rural, predominantly ethnic minority communities in northern Vietnam. Int J Ment Health Syst 2016;10:10.

86. Amstutz U, Ross CJ, Castro-Pastrana LI, Rieder MJ, Shear NH, Hayden MR, Carleton BC, Consortium C. HLA-A 31:01 and HLA-B 15:02 as genetic markers for carbamazepine hypersensitivity in children. Clin Pharmacol Ther 2013;94:142-9.

87. Grover S, Kukreti R. HLA alleles and hypersensitivity to carbamazepine: an updated systematic review with meta-analysis. Pharmacogenet Genomics 2014;24:94-112.
88. Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K, Furuya H, Takahashi Y, Muramatsu M, Kinoshita S, Abe M, Ikeda H, Kashiwagi M, Song Y, Ueta M, Sotozono C, Ikezawa Z, Hasegawa R; JSAR research group. HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Epilepsia 2010;51:2461-5.

PUBMED | CROSSREF

89. Amstutz U, Shear NH, Rieder MJ, Hwang S, Fung V, Nakamura H, Connolly MB, Ito S, Carleton BC; CPNDS clinical recommendation group. Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions. Epilepsia 2014;55:496-506.

PUBMED | CROSSREF

90. Shi YW, Min FL, Zhou D, Qin B, Wang J, Hu FY, Cheung YK, Zhou JH, Hu XS, Zhou JQ, Zhou LM, Zheng ZZ, Pan J, He N, Liu ZS, Hou YQ, Lim KS, Ou YM, Hui-Ping Khor A, Ng CC, Mao BI, Liu XR, Li BM, Kuan YY, Yi YH, He XL, Deng XY, Su T, Kwan P, Liao WP. HLA-A*24:02 as a common risk factor for antiepileptic drug-induced cutaneous adverse reactions. Neurology 2017;88:2183-91.

PUBMED | CROSSREF

91. Pirmohamed M, Lin K, Chadwick D, Park BK. TNFalpha promoter region gene polymorphisms in carbamazepine-hypersensitive patients. Neurology 2001;56:890-6.

PUBMED | CROSSREF

92. Trachtenberg E, Vinson M, Hayes E, Hsu YM, Houtchens K, Erlich H, Klitz W, Hsia Y, Hollenbach J. HLA class I (A, B, C) and class II (DRB1, DQA1, DQB1, DPB1) alleles and haplotypes in the Han from southern China. Tissue Antigens 2007;70:455-63.

PUBMED | CROSSREF

93. Alfirevic A, Mills T, Harrington P, Pinel T, Sherwood J, Jawaid A, Smith JC, March RE, Barratt BJ, Chadwick DW, Kevin Park B, Pirmohamed M. Serious carbamazepine-induced hypersensitivity reactions associated with the HSP70 gene cluster. Pharmacogenet Genomics 2006;16:287-96.

PUBMED | CROSSREF

94. Tassaneeyakul W, Jantararoungtong T, Chen P, Lin PY, Tiamkao S, Khunarkornsiri U, Chucherd P, Konyoung P, Vannapasraht S, Choonthakarn C, Pisuttimarn P, Sangviroon A, Tassaneeyakul W. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics 2009;19:704-9.

PUBMED | CROSSREF

95. Kang HR, Lee YK, Kim YS, Lee CH, Jung JW, Kim SH, Park HW, Chang YS, Jang II, Cho SH, Min KU, Kim SH, Lee KW; Adverse Drug Reaction Research Group in Korea. Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans. Pharmacogenet Genomics 2011;21:303-7.

PUBMED | CROSSREF

96. Tohkin M, Kaniwa N, Saito Y, Sugiyama E, Kurose K, Nishikawa I, Hasegawa R, Aihara M, Matsunaga K, Abe M, Furuya H, Takahashi Y, Ikeda H, Muramatsu M, Ueta M, Sotozono C, Kinoshita S, Ikezawa Z; Japan Pharmacogenomics Data Science Consortium. A whole-genome association study of major determinants for allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Pharmacogenomics J 2013;13:60-9.

PUBMED | CROSSREF

97. Somkrua R, Eickman EE, Saokaew S, Lohitnavy M, Chaiyakunapruk N. Association of HLA-B*5801 allele and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. BMC Med Genet 2011;12:118.

PUBMED | CROSSREF

98. Gonçalo M, Coutinho I, Teixeira V, Gameiro AR, Brites MM, Nunes R, Martins A. HLA-B*58:01 is a risk factor for allopurinol-induced DRESS and Stevens-Johnson syndrome/toxic epidermal necrolysis in a Portuguese population. Br J Dermatol 2013;169:660-5.

PUBMED | CROSSREF

99. Cristallo AF, Schroeder J, Citterio A, Santori G, Ferrioli GM, Rossi U, Bertani G, Cassano S, Gottardi P, Ceschin N, Barocci F, Ribizzi G, Cutrupi V, Cairoli R, Rapisarda V, Pastorello EA, Barocci S. A study of HLA class I and class II 4-digit allele level in Stevens-Johnson syndrome and toxic epidermal necrolysis. Int J Immunogenet 2011;38:303-9.

PUBMED | CROSSREF

100. Adam J, Pichler WJ, Yerly D. Delayed drug hypersensitivity: models of T-cell stimulation. Br J Clin Pharmacol 2011;71:701-7.

PUBMED | CROSSREF

101. Yun J, Cai F, Lee FJ, Pichler WJ. T-cell-mediated drug hypersensitivity: immune mechanisms and their clinical relevance. Asia Pac Allergy 2016;6:77-89.

PUBMED | CROSSREF
102. Redwood AJ, Pavlos RK, White KD, Phillips EJ. HLAs: key regulators of T-cell-mediated drug hypersensitivity. HLA 2018;91:3-16.

103. Sullivan A, Gibson A, Park BK, Naisbitt DJ. Are drug metabolites able to cause T-cell-mediated hypersensitivity reactions? Expert Opin Drug Metab Toxicol 2015;11:357-68.

104. Wei CY, Chung WH, Huang HW, Chen YT, Hung SI. Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome. J Allergy Clin Immunol 2012;129:1562-9.e5.

105. Posadas SJ, Padiel A, Torres MJ, Mayorga C, Leyva L, Sanchez E, Alvarez J, Romano A, Juarez C, Blanca M. Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity. J Allergy Clin Immunol 2002;109:155-61.

106. Chung WH, Hung SI, Yang JY, Su SC, Huang SP, Wei CY, Chin SW, Chiou CC, Chu SC, Ho HC, Yang CH, Lu CF, Wu JY, Liao YD, Chen YT. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med 2008;14:1343-50.

107. Ko TM, Chung WH, Wei CY, Shih HY, Chen JK, Lin CH, Chen YT, Hung SI. Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome. J Allergy Clin Immunol 2011;128:1266-76.e11.

108. Lichtenfels M, Farrell J, Ogese MO, Bell CC, Eckle S, McCluskey JP, Park BK, Altrevic A, Naisbitt DJ, Pirmohamed M. HLA restriction of carbamazepine-specific T-Cell clones from an HLA-A*31:01-positive hypersensitive patient. Chem Res Toxicol 2014;27:175-7.

109. Wu Y, Farrell J, Pirmohamed M, Park BK, Naisbitt DJ. Generation and characterization of antigen-specific CD4+, CD8+, and CD4+CD8+ T-cell clones from patients with carbamazepine hypersensitivity. J Allergy Clin Immunol 2007;119:973-81.

110. Yun J, Marcaida MJ, Eriksson KK, Jamin H, Fontana S, Pichler WJ, Yeley D. Oxyurinol directly and immediately activates the drug-specific T cells via the preferential use of HLA-B*58:01. J Immunol 2014;192:2984-93.

111. Blázquez AB, Cuesta J, Mayorga C. Role of dendritic cells in drug allergy. Curr Opin Allergy Clin Immunol 2011;11:279-84.

112. Pichler WJ, Adam J, Watkins S, Wuillemin N, Yun J, Yeley D. Drug hypersensitivity: how drugs stimulate T cells via pharmacological interaction with immune receptors. Int Arch Allergy Immunol 2015;168:13-24.

113. Bellón T, Alvarez L, Mayorga C, Morel E, Torres MJ, Martin-Diaz MA, Diaz R, Radial A, Carballo M, Blanca M. Differential gene expression in drug hypersensitivity reactions: induction of alarmins in severe bullous diseases. Br J Dermatol 2010;162:1014-22.

114. Oppenheim JJ, Yang D. Alarmins: chemotactic activators of immune responses. Curr Opin Immunol 2005;17:359-65.

115. Nakajima A, Oda S, Yokoi T. Allopurinol induces innate immune responses through mitogen-activated protein kinase signaling pathways in HL-60 cells. J Appl Toxicol 2016;36:1120-8.

116. Michels AW, Ostrov DA. New approaches for predicting T cell-mediated drug reactions: A role for inducible and potentially preventable autoimmunity? J Allergy Clin Immunol 2015;136:252-7.
118. Obata Y, Furusawa Y, Hase K. Epigenetic modifications of the immune system in health and disease. Immunol Cell Biol 2015;93:226-32.

119. Morandini AC, Santos CF, Yilmaz Ö. Role of epigenetics in modulation of immune response at the junction of host-pathogen interaction and danger molecule signaling. Pathog Dis 2016;74:ftw082.

120. Sawalha AH. Epigenetics and T-cell immunity. Autoimmunity 2008;41:245-52.

121. Zhang X, Liu J, Cao X. Metabolic control of T-cell immunity via epigenetic mechanisms. Cell Mol Immunol 2018;15:203-5.

122. Moggs JG, Terranova R, Kammüller ME, Chibout SD, Chapman V, Dearman RJ, Kimber I. Regulation of allergic responses to chemicals and drugs: possible roles of epigenetic mechanisms. Toxicol Sci 2012;130:60-9.

123. Sun B, Cheng L, Xiong Y, Hu L, Luo Z, Zhou M, Li J, Xie H, He F, Yuan X, Chen X, Zhou HH, Liu Z, Chen X, Zhang W. PSORS1C1 Hypomethylation Is associated with allopurinol-induced severe cutaneous adverse reactions during disease onset period: a multicenter retrospective case-control clinical study in Han Chinese. Front Pharmacol 2018;8:923.

124. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005;120:15-20.

125. Boosani CS, Agrawal DK. Epigenetic regulation of innate immunity by microRNAs. Antibodies 2016;5:8.

126. Ichihara A, Wang Z, Jinnin M, Izuno Y, Shimozano N, Yamane K, Fujisawa A, Moriya C, Fukushima S, Inoue Y, Ihn H. Upregulation of miR-38a-5p contributes to epidermal necrolysis in severe drug eruptions. J Allergy Clin Immunol 2014;133:1065-74.

127. Sato S, Ichihara A, Jinnin M, Izuno Y, Fukushima S, Ihn H. Serum miR-124 up-regulation as a disease marker of toxic epidermal necrosis. Eur J Dermatol 2015;25:457-62.

128. Monroy-Aroela A, Durán-Figueroa NV, Méndez-Flores S, Domínguez-Cherit J, Watkinson J, Badillo-Corona JA, Whitaker P, Naishott DJ, Castrejón-Flores JL. Up-regulation of T-cell activation microRNAs in drug-specific CD4(+) T-cells from hypersensitive patients. Chem Res Toxicol 2018;31:454-61.

129. Kulkarni S, Savan R, Qi Y, Gao X, Yuki Y, Bass SE, Martin MP, Hunt P, Deeks SG, Telent L, Perez FA, Goldstein D, Wolinsky S, Walker B, Young HA, Carrington M. Differential microRNA regulation of HLA-C expression and its association with HIV control. Nature 2011;472:495-8.

130. Ginsburg CM. Stevens-Johnson syndrome in children. Pediatr Infect Dis 1982;1:155-8.

131. Halebian PH, Corder VJ, Madden MR, Finklestein JL, Shires GT. Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg 1986;204:503-12.

132. Kelemen JJ 3rd, Ciuffi WG, McManus WF, Mason AD Jr, Pruitt BA Jr. Burn center care for patients with toxic epidermal necrosis. J Am Coll Surg 1995;180:273-8.

133. Huang YC, Li YC, Chen TJ. The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrosis: a systematic review and meta-analysis. Br J Dermatol 2012;167:424-32.

134. Lee HY, Lim YL, Thirumooorthy T, Pang SM. The role of intravenous immunoglobulin in toxic epidermal necrosis: a retrospective analysis of 64 patients managed in a specialized centre. Br J Dermatol 2013;169:1304-9.

135. Kirchhof MG, Miliszewski MA, Sikora S, Papp A, Dutz JP. Retrospective review of Stevens-Johnson syndrome/toxic epidermal necrosis treatment comparing intravenous immunoglobulin with cyclosporine. J Am Acad Dermatol 2014;71:941-7.
136. Lee HY, Fook-Chong S, Koh HY, Thirumoorthy T, Pang SM. Cyclosporine treatment for Stevens-Johnson syndrome/toxic epidermal necrolysis: retrospective analysis of a cohort treated in a specialized referral center. J Am Acad Dermatol 2017;76:106-13.

137. Wojtkiewicz A, Wysocki M, Fortuna J, Chrupek M, Matczuk M, Koltan A. Beneficial and rapid effect of infliximab on the course of toxic epidermal necrolysis. Acta Derm Venereol 2008;88:420-1.

138. Zárate-Correa LC, Carrillo-Gómez DC, Ramírez-Escobar AF, Serrano-Reyes C. Toxic epidermal necrolysis successfully treated with infliximab. J Investig Allergol Clin Immunol 2013;23:61-3.

139. Scott-Lang V, Tidman M, McKay D. Toxic epidermal necrolysis in a child successfully treated with infliximab. Pediatr Dermatol 2014;31:532-4.

140. Natkunarajah J, Goolamali S, Craythorne E, Benton E, Smith C, Morris-Jones R, Wendon J, Higgins E, Creamer D. Ten cases of drug reaction with eosinophilia and systemic symptoms (DRESS) treated with pulsed intravenous methylprednisolone. Eur J Dermatol 2011;21:385-91.

141. Marcus N, Smuel K, Almog M, Prais D, Straussberg R, Landau D, Scheuerman O. Successful intravenous immunoglobulin treatment in pediatric severe DRESS syndrome. J Allergy Clin Immunol Pract 2018;6:1238-42.

142. Galvão VR, Aun MV, Kalil J, Castells M, Giavina-Bianchi P. Clinical and laboratory improvement after intravenous immunoglobulin in drug reaction with eosinophilia and systemic symptoms. J Allergy Clin Immunol Pract 2014;2:107-10.

143. Hotz C, Valeyrie-Allanore L, Haddad C, Bouvresse S, Ortonne N, Duong TA, Ingen-Housz-Oro S, Roujeau JC, Wolkenstein P, Chosidow O. Systemic involvement of acute generalized exanthematous pustulosis: a retrospective study on 58 patients. Br J Dermatol 2013;169:1223-32.

144. Kulkantrakorn K, Tassaneeyakul W, Tiamkao S, Jantaraarongtong T, Prabmechai N, Vannaprasaht S, Chumworathayi P, Chen P, Sititsipukho P. HLA-B*1502 strongly predicts carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Thai patients with neuropathic pain. Pain Pract 2012;12:202-8.

145. Then SM, Rani ZZ, Raymond AA, Ratnaringrum S, Jamal R. Frequency of the HLA-B*1502 allele contributing to carbamazepine-induced hypersensitivity reactions in a cohort of Malaysian epilepsy patients. Asian Pac J Allergy Immunol 2011;29:290-3.

146. Chiu ML, Hu M, Ng MH, Yeung CK, Chan JC, Chang MM, Cheng SH, Li L, Tomlinson B. Association between HLA-B*58:01 allele and severe cutaneous adverse reactions with allopurinol in Han Chinese in Hong Kong. Br J Dermatol 2012;167:44-9.